Hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 2009,

Hypomethylating agent induces expression of NXF2, an immunogenic cancer testis antigen. Clin Cancer Res 2009, 15:3406-3415. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, Kondo Y, Sekido Y, Kawatsura H, Narita Y, Yoshida J: The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 2008, 122:2542-2553. Almstedt M, Blagitko-Dorfs N, Duque-Afonso J, Karbach J, Pfeifer D, Jager E, Lubbert M: The DNA demethylating agent 5-aza-2′-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells. Leuk Res 2010, 34:899-905. Coral S, Sigalotti L, Gasparollo A, Cattarossi I, Visintin A, Cattelan A, Altomonte M, Maio M: Prolonged upregulation of the expression of HLA class I antigens and costimulatory molecules on melanoma cells treated with 5-aza-2′-deoxycytidine (5-AZA-CdR). J Immunother 1999, 22:16-24.Konkankit et al. Journal of Translational Medicine 2011, 9:192 http://www.translational-medicine.com/content/9/1/Page 13 of24. Patra SK, Bettuzzi S: Epigenetic DNA-(cytosine-5-carbon) modifications: 5aza-2′-deoxycytidine and DNA-demethylation. Biochemistry (Mosc) 2009, 74:613-619. 25. Esteller M: DNA methylation and cancer therapy: new developments and expectations. Curr Opin Oncol 2005, 17:55-60. 26. Daskalakis M, Blagitko-Dorfs N, Hackanson B: Decitabine. Recent Results Cancer Res 2010, 184:131-157. 27. Watanabe Y, Maekawa M: Methylation of DNA in cancer. Adv Clin Chem 2010, 52:145-167. 28. Jones PA, Buckley JD: The role of DNA methylation in cancer. Adv Cancer Res 1990, 54:1-23. 29. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM: Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011, 17:1603-1615. 30. Robbins PF, Li YF, El-Gamil M, Zhao Y, Wargo JA, Zheng Z, Xu H, Morgan RA, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28878015 Feldman SA, Johnson LA, et al: Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol 2008, 180:6116-6131. 31. Kwong GA, Radu CG, Hwang K, Shu CJ, Ma C, Koya RC, Comin-Anduix B, Hadrup SR, Bailey RC, Witte ON, et al: Modular nucleic acid assembled p/ MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc 2009, 131:9695-9703. 32. Prins RM, Odesa SK, Liau LM: Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003, 63:8487-8491. 33. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA: Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281:65-78. 34. Caballero OL, Chen YT: Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 2009, 100:2014-2021. 35. Parney IF, Hao C, Petruk KC: Glioma immunology and immunotherapy. Neurosurgery 2000, 46:778-791, discussion 791-772. 36. Janssen EM, Lemmens EE, Gour N, Reboulet RA, Green DR, Schoenberger SP, Litronesib chemical information Pinkoski MJ: Distinct roles of cytolytic effector molecules for antigen-restricted killing by CTL in vivo. Immunol Cell Biol 2010, 88:761-765. 37. Jazirehi AR, Baritaki S, Koya RC, Bonavida B, Economou JS: Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction. Cancer research 2011, 71:1406-1417. 38. Krakstad C, Chekenya M: Survi.